Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

(2016) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer

(2015) Peter M. Ellis et al.   Clinical Lung Cancer

Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1

(2015) Chung-Pu Wu et al.   MOLECULAR PHARMACEUTICS

Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases

(2015) Eleonore Beurel et al.   PHARMACOLOGY & THERAPEUTICS

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

(2015) Xiaoqi Liu   Translational Oncology

BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536

(2015) Lijia Chen et al.   ACS Medicinal Chemistry Letters

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

(2014) H. Dohner et al.   BLOOD

Overexpression of Human ABCB1 in Cancer Cells Leads to Reduced Activity of GSK461364, a Specific Inhibitor of Polo-like Kinase 1

(2014) Chung-Pu Wu et al.   MOLECULAR PHARMACEUTICS

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

(2014) Pietro Ciceri et al.   Nature Chemical Biology

Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1

(2013) Chung-Pu Wu et al.   BIOCHEMICAL PHARMACOLOGY

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

(2013) Walter M. Stadler et al.   CANCER

Enabling and Disabling Polo-like Kinase 1 Inhibition through Chemical Genetics

(2012) Mark E. Burkard et al.   ACS Chemical Biology

Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance

(2012) Alexander Levitzki   Annual Review of Pharmacology and Toxicology

From Plk1 to Plk5

(2011) Guillermo de Cárcer et al.   CELL CYCLE

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

(2011) D. Olmos et al.   CLINICAL CANCER RESEARCH

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Functional availability of γ-herpesvirus K-cyclin is regulated by cellular CDK6 and p16INK4a

(2010) Hidenori Yoshioka et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Distinct Concentration-Dependent Effects of the Polo-like Kinase 1-Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

(2009) A. G. Gilmartin et al.   CANCER RESEARCH

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Apoptotic signaling by c-MYC

(2008) B Hoffman et al.   ONCOGENE